Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Guggenheim

Key Points

• Guggenheim upgraded Tyra Biosciences (NASDAQ:TYRA) to a strong-buy, and the analyst consensus is a Buy with a consensus target price of $46.50.
• TYRA traded around $34.97 with a market cap of $1.88 billion and a 52-week range of $7.80–$40.65; the company recently missed quarterly EPS (‑$0.57 vs. ‑$0.54) and analysts expect about ‑$1.57 EPS for the current fiscal year.
• Insider and institutional positioning: a director sold 14,295 shares (a 33.61% reduction in their holdings), insiders own 15.20% of the stock, and institutional investors own roughly 84.14%.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) was upgraded by investment analysts at Guggenheim to a "strong-buy" rating in a research note issued on Tuesday,Zacks.com reports.

TYRA has been the topic of a number of other research reports. William Blair assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, February 10th. They set an "outperform" rating on the stock. Wall Street Zen lowered shares of Tyra Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, January 24th. Barclays assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They set an "overweight" rating on the stock. Cantor Fitzgerald assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, February 24th. They set an "overweight" rating on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $46.50.

Tyra Biosciences Stock Down 0.9%

TYRA opened at $34.97 on Tuesday. The firm has a market capitalization of $1.88 billion, a P/E ratio of -17.40 and a beta of 0.96. The firm's 50 day moving average is $34.58 and its 200-day moving average is $26.00. Tyra Biosciences has a 52-week low of $7.80 and a 52-week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Equities analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Gilla Kaplan sold 14,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director owned 28,231 shares of the company's stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.20% of the company's stock.

Institutional Trading of Tyra Biosciences

Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth approximately $51,000. Chung Wu Investment Group LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth approximately $53,000. Federated Hermes Inc. grew its position in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company's stock worth $30,000 after buying an additional 1,841 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company's stock worth $68,000 after buying an additional 534 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences in the fourth quarter worth $220,000. Institutional investors and hedge funds own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.